NASDAQ:HBIO - Harvard Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.29 -0.11 (-2.50 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$4.29
Today's Range$4.25 - $4.46
52-Week Range$2.95 - $6.70
Volume72,119 shs
Average Volume154,268 shs
Market Capitalization$160.95 million
P/E Ratio85.80
Dividend YieldN/A
Beta1.07
Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion controllers, temperature controllers, microincubation systems, and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions. Harvard Bioscience, Inc. markets its products in approximately 100 countries through sales organization, Websites, catalogs, and distributors to research scientists at universities, hospitals, government laboratories, and pharmaceutical and biotechnology companies. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Receive HBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNASDAQ:HBIO
CUSIP41690610
Phone508-893-8999

Debt

Debt-to-Equity Ratio0.78
Current Ratio2.42
Quick Ratio1.26

Price-To-Earnings

Trailing P/E Ratio85.80
Forward P/E Ratio35.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$101.88 million
Price / Sales1.54
Cash Flow$0.16 per share
Price / Cash26.82
Book Value$2.32 per share
Price / Book1.85

Profitability

EPS (Most Recent Fiscal Year)$0.05
Net Income$-860,000.00
Net Margins-4.46%
Return on Equity4.64%
Return on Assets2.62%

Miscellaneous

Employees434
Outstanding Shares36,580,000
Market Cap$160.95 million

Harvard Bioscience (NASDAQ:HBIO) Frequently Asked Questions

What is Harvard Bioscience's stock symbol?

Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO."

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) posted its quarterly earnings results on Thursday, July, 26th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.05 by $0.02. The medical instruments supplier earned $31.52 million during the quarter, compared to the consensus estimate of $30.50 million. Harvard Bioscience had a negative net margin of 4.46% and a positive return on equity of 4.64%. View Harvard Bioscience's Earnings History.

When is Harvard Bioscience's next earnings date?

Harvard Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, October 25th 2018. View Earnings Estimates for Harvard Bioscience.

What price target have analysts set for HBIO?

2 analysts have issued 1-year target prices for Harvard Bioscience's stock. Their forecasts range from $8.00 to $11.00. On average, they expect Harvard Bioscience's stock price to reach $9.50 in the next year. This suggests a possible upside of 121.4% from the stock's current price. View Analyst Price Targets for Harvard Bioscience.

What is the consensus analysts' recommendation for Harvard Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harvard Bioscience.

Who are some of Harvard Bioscience's key competitors?

Who are Harvard Bioscience's key executives?

Harvard Bioscience's management team includes the folowing people:
  • Mr. Jeffrey A. Duchemin, CEO, Pres & Director (Age 52)
  • Mr. Yong Sun, VP & GM of Physiology, Cell and Molecular Instruments (Age 54)
  • Mr. Corey Manchester, VP & Corp. Controller
  • Mr. Karl-Heinz Boven, VP & GM of Electrophysiology

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (1.43%), Foundry Partners LLC (1.12%) and Strs Ohio (0.26%). Company insiders that own Harvard Bioscience stock include David Green, Earl R Lewis, George Uveges, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Institutional Ownership Trends for Harvard Bioscience.

Which major investors are selling Harvard Bioscience stock?

HBIO stock was sold by a variety of institutional investors in the last quarter, including Foundry Partners LLC. Company insiders that have sold Harvard Bioscience company stock in the last year include George Uveges, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

Which major investors are buying Harvard Bioscience stock?

HBIO stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Strs Ohio. Company insiders that have bought Harvard Bioscience stock in the last two years include Earl R Lewis, James W Green, Jeffrey Duchemin and Robert E Gagnon. View Insider Buying and Selling for Harvard Bioscience.

How do I buy shares of Harvard Bioscience?

Shares of HBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Harvard Bioscience's stock price today?

One share of HBIO stock can currently be purchased for approximately $4.29.

How big of a company is Harvard Bioscience?

Harvard Bioscience has a market capitalization of $160.95 million and generates $101.88 million in revenue each year. The medical instruments supplier earns $-860,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Harvard Bioscience employs 434 workers across the globe.

What is Harvard Bioscience's official website?

The official website for Harvard Bioscience is http://www.harvardbioscience.com.

How can I contact Harvard Bioscience?

Harvard Bioscience's mailing address is 84 OCTOBER HILL ROAD, HOLLISTON MA, 01746. The medical instruments supplier can be reached via phone at 508-893-8999 or via email at [email protected]


MarketBeat Community Rating for Harvard Bioscience (NASDAQ HBIO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  159 (Vote Underperform)
Total Votes:  331
MarketBeat's community ratings are surveys of what our community members think about Harvard Bioscience and other stocks. Vote "Outperform" if you believe HBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel